J M Satagopan

Summary

Affiliation: Memorial Sloan-Kettering Cancer Center
Country: USA

Publications

  1. pmc Evaluation of removable statistical interaction for binary traits
    Jaya M Satagopan
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Stat Med 32:1164-90. 2013
  2. pmc Copy number and gene expression differences between African American and Caucasian American prostate cancer
    Amy E Rose
    Department of Urology, New York University School of Medicine, New York, New York 10016, USA
    J Transl Med 8:70. 2010
  3. pmc Frequency of CHEK2*1100delC in New York breast cancer cases and controls
    Kenneth Offit
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    BMC Med Genet 4:1. 2003
  4. pmc Analysis of genetic variation in Ashkenazi Jews by high density SNP genotyping
    Adam B Olshen
    Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    BMC Genet 9:14. 2008
  5. ncbi request reprint Sequential quantitative trait locus mapping in experimental crosses
    Jaya M Satagopan
    Memorial Sloan Kettering Cancer Center, USA
    Stat Appl Genet Mol Biol 6:Article12. 2007
  6. ncbi request reprint Two-stage designs for gene-disease association studies with sample size constraints
    Jaya M Satagopan
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Biometrics 60:589-97. 2004
  7. pmc A note on competing risks in survival data analysis
    J M Satagopan
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York 10021, USA
    Br J Cancer 91:1229-35. 2004
  8. ncbi request reprint Optimal two-stage genotyping in population-based association studies
    Jaya M Satagopan
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Genet Epidemiol 25:149-57. 2003
  9. ncbi request reprint Frequency of BRCA1 and BRCA2 mutations in unselected Ashkenazi Jewish patients with colorectal cancer
    Tomas Kirchhoff
    Clinical Genetics Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Natl Cancer Inst 96:68-70. 2004
  10. ncbi request reprint Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation
    Noah D Kauff
    Clinical Genetics Service, Memorial Sloan Kettering Cancer Center, New York 10021, USA
    N Engl J Med 346:1609-15. 2002

Research Grants

Detail Information

Publications28

  1. pmc Evaluation of removable statistical interaction for binary traits
    Jaya M Satagopan
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Stat Med 32:1164-90. 2013
    ..We illustrate the proposed test and use of the transformation by using case-control data from three published studies. Finally, we indicate how one can check that, after transformation, no further interaction is significant...
  2. pmc Copy number and gene expression differences between African American and Caucasian American prostate cancer
    Amy E Rose
    Department of Urology, New York University School of Medicine, New York, New York 10016, USA
    J Transl Med 8:70. 2010
    ....
  3. pmc Frequency of CHEK2*1100delC in New York breast cancer cases and controls
    Kenneth Offit
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    BMC Med Genet 4:1. 2003
    ..While the frequency of 1100delC was 1.1-1.4% in healthy Finnish controls, the frequency of this allele in a North American control population and in North American breast cancer kindreds remains unclear...
  4. pmc Analysis of genetic variation in Ashkenazi Jews by high density SNP genotyping
    Adam B Olshen
    Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    BMC Genet 9:14. 2008
    ..435,632 SNPs overlapped and met annotation criteria in the two groups...
  5. ncbi request reprint Sequential quantitative trait locus mapping in experimental crosses
    Jaya M Satagopan
    Memorial Sloan Kettering Cancer Center, USA
    Stat Appl Genet Mol Biol 6:Article12. 2007
    ..We examine settings under which the two-stage analytic approach provides sufficient power to detect the putative QTLs...
  6. ncbi request reprint Two-stage designs for gene-disease association studies with sample size constraints
    Jaya M Satagopan
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Biometrics 60:589-97. 2004
    ....
  7. pmc A note on competing risks in survival data analysis
    J M Satagopan
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York 10021, USA
    Br J Cancer 91:1229-35. 2004
    ..We compare the resulting estimates with those obtained using the Kaplan-Meier approach to demonstrate the importance of appropriately estimating the cumulative incidence of an event of interest in the presence of competing risk events...
  8. ncbi request reprint Optimal two-stage genotyping in population-based association studies
    Jaya M Satagopan
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Genet Epidemiol 25:149-57. 2003
    ..The results show that, compared to a one-stage approach, a two-stage procedure typically halves the cost of the study...
  9. ncbi request reprint Frequency of BRCA1 and BRCA2 mutations in unselected Ashkenazi Jewish patients with colorectal cancer
    Tomas Kirchhoff
    Clinical Genetics Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Natl Cancer Inst 96:68-70. 2004
    ..22 to 1.14). We thus recommend that counseling for colorectal cancer screening and prevention in individuals with BRCA mutations be based on the personal and family history of colorectal cancer or associated syndromic malignancies...
  10. ncbi request reprint Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation
    Noah D Kauff
    Clinical Genetics Service, Memorial Sloan Kettering Cancer Center, New York 10021, USA
    N Engl J Med 346:1609-15. 2002
    ..We prospectively compared the effect of risk-reducing salpingo-oophorectomy with that of surveillance for ovarian cancer on the incidence of subsequent breast cancer and BRCA-related gynecologic cancers in women with BRCA mutations...
  11. ncbi request reprint BRCA1 and BRCA2 germline mutations in lymphoma patients
    Orit Yossepowitch
    Clinical Genetics Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Leuk Lymphoma 44:127-31. 2003
    ..This data indicate that germline BRCA mutations are not associated with an increased risk for lymphoid malignancies...
  12. pmc Quantitative trait locus study design from an information perspective
    Saunak Sen
    Department of Epidemiology and Biostatistics, University of California, San Francisco, 94143, USA
    Genetics 170:447-64. 2005
    ..Software for performing power calculations for backcross and F(2) intercross incorporating selective genotyping and marker spacing is available from http://www.biostat.ucsf.edu/sen...
  13. ncbi request reprint A statistical perspective on gene expression data analysis
    Jaya M Satagopan
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Stat Med 22:481-99. 2003
    ..S-plus and SAS codes to perform the statistical methods are provided. Gene expression data from an unpublished oncologic study is used to illustrate these methods...
  14. pmc Study of Nevi in Children (SONIC): baseline findings and predictors of nevus count
    Susan A Oliveria
    Dermatology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10022, USA
    Am J Epidemiol 169:41-53. 2009
    ..041), and often and always (RR = 1.32, 95% CI: 1.13, 1.54; P = 0.001) were associated with increased number of nevi. Identifying factors that predict the development of nevi will improve primary prevention efforts during early life...
  15. pmc TMPRSS2-ERG gene fusion is not associated with outcome in patients treated by prostatectomy
    Anuradha Gopalan
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Cancer Res 69:1400-6. 2009
    ....
  16. ncbi request reprint Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations
    Jaya M Satagopan
    Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 8:3776-81. 2002
    ..To address this, we have used a case-control design that does not involve familial aggregation to estimate the lifetime penetrance of ovarian cancer due to BRCA1 and BRCA2 mutations...
  17. pmc Normalization method for transcriptional studies of heterogeneous samples--simultaneous array normalization and identification of equivalent expression
    Li Xuan Qin
    Memorial Sloan Kettering Cancer Center
    Stat Appl Genet Mol Biol 8:Article 10. 2009
    ..Empirical illustration of the proposed method is provided using a liposarcoma study from MSKCC to identify genes differentially expressed between normal fat tissue versus liposarcoma tissue samples...
  18. pmc TMPRSS2-ERG gene fusion is associated with low Gleason scores and not with high-grade morphological features
    Samson W Fine
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Mod Pathol 23:1325-33. 2010
    ..These findings indicate that translocation/deletion of TMPRSS2-ERG is not associated with histological features of aggressive prostate cancer...
  19. ncbi request reprint Two-stage designs for gene-disease association studies
    Jaya M Satagopan
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Biometrics 58:163-70. 2002
    ..This translates to screening all the markers on approximately one quarter of the required sample size in stage 1...
  20. pmc A bayesian approach to detect quantitative trait loci using Markov chain Monte Carlo
    J M Satagopan
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York 10021 6094, USA
    Genetics 144:805-16. 1996
    ..High posterior density regions of the marginal densities are obtained as confidence regions. We examine flowering time data from double haploid progeny of Brassica napus to illustrate the proposed method...
  21. ncbi request reprint The lifetime risks of breast cancer in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations
    J M Satagopan
    Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA
    Cancer Epidemiol Biomarkers Prev 10:467-73. 2001
    ..The risks appear to be different for carriers of BRCA1 and BRCA2 mutations...
  22. ncbi request reprint Rare variants of ATM and risk for Hodgkin's disease and radiation-associated breast cancers
    Kenneth Offit
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 8:3813-9. 2002
    ..We next sought to determine the frequency of ATM variants in patients with Hodgkin's lymphoma, regardless of coexisting BC, compared with healthy volunteers...
  23. pmc R/qtlDesign: inbred line cross experimental design
    Saunak Sen
    Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California 94143, USA
    Mamm Genome 18:87-93. 2007
    ..We give examples of software usage in real-life settings. The software is available at http://www.biostat.ucsf.edu/sen/software.html ...
  24. ncbi request reprint Novel mutations of epidermal growth factor receptor in localized prostate cancer
    Diah A Douglas
    Department of Urology, New York University School of Medicine, New York, NY 10016, USA
    Front Biosci 11:2518-25. 2006
    ..Larger population-based studies are required to define the association between EGFR mutations and the ethnic background of patients...
  25. ncbi request reprint Assessing interactions between mdm-2, p53, and bcl-2 as prognostic variables in muscle-invasive bladder cancer treated with neo-adjuvant chemotherapy followed by locoregional surgical treatment
    F C Maluf
    The Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center and the Department of Medicine, Joan and Sanford Weill Medical College of Cornell University, New York, USA
    Ann Oncol 17:1677-86. 2006
    ..Both individual and cooperative effects of these gene products may affect the biological behavior of primary bladder cancers and long-term outcome to standard therapy...
  26. ncbi request reprint Type I transforming growth factor beta receptor maps to 9q22 and exhibits a polymorphism and a rare variant within a polyalanine tract
    B Pasche
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer Res 58:2727-32. 1998
    ..The clinical and biological significance of TbetaR-I(6A) homozygosity needs to be further investigated...
  27. pmc Genetic heterogeneity among Fanconi anemia heterozygotes and risk of cancer
    Marianne Berwick
    Cancer Research and Treatment Center Internal Medicine, University of New Mexico, Albuquerque, New Mexico, USA
    Cancer Res 67:9591-6. 2007
    ..4; 95% CI, 1.1-5.2). Overall, there was no increased risk for cancer among FA heterozygotes in this study of Fanconi relatives, although there is some evidence that FANCC mutations are possibly breast cancer susceptibility alleles...
  28. ncbi request reprint Absence of a telomere maintenance mechanism as a favorable prognostic factor in patients with osteosarcoma
    Gary A Ulaner
    Medical Service, Veterans Administration Palo Alto Health Care System, and Department of Medicine, Stanford University, Palo Alto, California 94304, USA
    Cancer Res 63:1759-63. 2003
    ..Finally, we note that OS cases with a TA-/ALT+ phenotype seem to be as clinically aggressive as TA+ cases in terms of stage and clinical outcome...

Research Grants5

  1. TWO STAGE DESIGNS FOR LINKAGE DISEQUILIBRIUM
    Jaya Satagopan; Fiscal Year: 2002
    ..abstract_text> ..
  2. STUDY OF EXPOSURES, BEHAVIORS, AND BIOMARKERS IN CANCER EPIDEMIOLOGY
    Jaya M Satagopan; Fiscal Year: 2010
    ..These render data analysis a challenging task. The long-term goals of this proposal are to investigate novel methods for efficient analyses of correlated risk factors, and to develop optimal study designs for follow-up research. ..